$16.67
-0.35 (-2.06%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MESO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
31 interventional · 3 expanded access · 5 with posted results
Held by 6 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, +1 more) · FINRA short interest 11.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host DiseaseNCT07568535Overall responseRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Remestemcel-L-rknd · Other: Placebo | GVHD - Graft-Versus-Host Disease | 180 | 2028-02-28 | in 558 d | 2026-05-05 |
| Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainNCT06325566Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) ScoreRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Rexlemestrocel-L + HA mixture, Saline | Degenerative Disc Disease | 300 | Jul 2027 | ≤ 346 d | 2026-06-17 |
| Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial InfarctionNCT01781390results2022-01-18Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Other: Placebo · Biological: Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M | Acute Myocardial Infarction | 106 | 2021-04-06actual | — | 2022-06-23 |
| Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back PainNCT02412735results2022-01-18Overall Treatment Success: Bayesian Estimated Response RateRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture, Placebo | Degenerative Disc Disease | 404 | 2020-05-15actual | — | 2022-10-19 |
| Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureNCT02032004results2026-03-23Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Rexlemestrocel-L · Other: Sham Comparator | Chronic Heart Failure | 565 | 2020-01-30actual | — | 2026-03-23 |
| Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHDNCT02652130results2022-03-16Overall Survival Rate Through Day 180Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Remestemcel-L | Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease | 32 | 2018-06-15actual | — | 2022-03-16 |
| A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)NCT02336230results2022-03-17Overall Response Rate (ORR) at Day 28 Post Initiation of TherapyOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: remestemcel-L | Grade B aGVHD, Grade C aGVHD, Grade D aGVHD | 55 | 2018-04-09actual | — | 2022-03-17 |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic MalignanciesNCT01854567Time to Neutrophil and Platelet EngraftmentRandomized · Open-label · Treatment | Phase 3 | Completed | Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units. | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease | 49 | 2016-09-23actual | — | 2020-06-26 |
| A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα InhibitorNCT01851070Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusionRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Allogeneic Mesenchymal Precursor Cells, Normal Saline | Rheumatoid Arthritis | 48 | May 2016actual | — | 2020-06-26 |
| Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic NephropathyNCT01843387The primary objective of the study is to assess the safety and tolerability of MPC therapyRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Biological: Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs) | Diabetic Nephropathy, Type 2 Diabetes | 30 | Sep 2014actual | — | 2016-10-14 |
| Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseNCT00482092Disease remission (CDAI at or below 150)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Prochymal®, Placebo | Crohn's Disease | 330 | 2014-09-15actual | — | 2026-03-11 |
| Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseNCT01233960Disease remissionOpen-label · Treatment | Phase 3 | Completed | Drug: Prochymal® | Crohn's Disease | 73 | 2014-09-15actual | — | 2026-03-11 |
| Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament ReconstructionNCT01088191To determine the overall safety of MSB-CAR001 plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Biological: MSB-CAR001 Combined With Hyaluronan · Drug: Hyaluronan | Anterior Cruciate Ligament Injury, Osteoarthritis | 17 | Nov 2013actual | — | 2018-08-15 |
| Safety Study of Mesenchymal Precursor Cells in Type 2 DiabetesNCT01576328Primary objective of the study is to assess the safety and tolerability of MPC therapyRandomized · Single-masked · Treatment | Phase 1/2 | Completed | Drug: Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs) | Type 2 Diabetes | 61 | Oct 2013actual | — | 2020-06-02 |
| Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)NCT00549913To determine the safety of NeoFuse (allogeneic mesenchymal precursor cells [MPCs]) when combined with MasterGraft Resorbable Ceramic Granules as a carrier for posterolateral lumbar fusion with instrumentation.Randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: NeoFuse · Procedure: posterolateral spinal fusion with instrumentation | Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis | 6 | Aug 2013actual | — | 2020-06-29 |
| Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical DiscectomyNCT01097486To determine the safety of NeoFuse using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and and immunology).Randomized · Single-masked · Treatment | Phase 2 | Completed | Biological: NeoFuse · Procedure: Allograft | Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis | 24 | Jul 2013actual | — | 2019-08-16 |
| Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back PainNCT01290367To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).Randomized · Double-masked · Treatment | Phase 2 | Completed | Biological: Single Dose MPCs Injection, Single Dose MPCs Injection · Procedure: Single injection of saline solution, Single injection of hyaluronic acid | Degenerative Disc Disease | 100 | Jul 2013actual | — | 2020-06-26 |
| Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody FusionNCT00996073To determine the overall safety of NeoFuse plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).Randomized · Single-masked · Treatment | Phase 2 | Completed | Biological: Lumbar Interbody Fusion with Autograft, Lumbar Interbody Fusion with NeoFuse, Lumbar Interbody Fusion with NeoFuse | Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis | 24 | Jul 2012actual | — | 2020-06-29 |
| Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and FusionNCT01106417Safety of NeoFuseRandomized · Single-masked · Treatment | Phase 1/2 | Completed | Biological: NeoFuse · Device: MasterGraft Granules | Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis | 12 | May 2012actual | — | 2020-06-29 |
| Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar FusionNCT00810212To determine the safety of NeoFuse (allogeneic mesenchymal precursor cells [MPCs] when combined with MasterGraft Resorbable Ceramic granules as a carrier for posterolateral lumbar fusion (PLF) with instrumentationRandomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor preferred a better study design | Procedure: PLF with autograft · Biological: PLF with NeoFuse, PLF with NeoFuse, PLF with NeoFuse | Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis | 0 | Nov 2011 | — | 2020-06-02 |
| A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart FailureNCT00721045The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.Randomized · Single-masked · Treatment | Phase 2 | Completed | Biological: Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs), Mesenchymal Precursor Cells (MPCs) · Procedure: standard-of-care treatment with mock mapping and injection procedures., standard-of-care treatment with mock mapping and injection procedures., standard-of-care treatment with mock mapping and injection procedures. | Heart Failure | 60 | Jun 2011actual | — | 2020-03-11 |
| Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)NCT00877903Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Prochymal®, Placebo | Myocardial Infarction | 220 | 2011-05-18actual | — | 2026-03-11 |
| PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)NCT00690066C-peptide area under the concentration curve (AUC) response (MMTT)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: PROCHYMAL®, Placebo | Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes | 63 | 2010-12-12actual | — | 2026-03-11 |
| Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseNCT00543374Duration of clinical benefit (Crohn's disease activity index)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, PROCHYMAL adult human mesenchymal stem cells | Crohn's Disease | 98 | Jul 2009actual | — | 2026-03-11 |
| Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)NCT00562497Percentage of Participants with Treatment SuccessRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Prochymal® · Other: Placebo, Corticosteroid | Graft Versus Host Disease | 192 | 2009-07-14actual | — | 2022-01-19 |
| PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00683722Number of Participants with Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Prochymal™, Placebo | Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis | 62 | 2009-03-09actual | — | 2026-03-11 |
| Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)NCT00366145Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days DurationRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Prochymal® · Drug: Placebo, Standard of Care for GVHD | Graft Versus Host Disease | 260 | 2008-12-26actual | — | 2022-02-10 |
| Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial InfarctionNCT00114452Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: Provacel, Placebo | Myocardial Infarction | 60 | 2006-10-04actual | — | 2020-03-10 |
| Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)NCT00136903Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil | Graft Vs Host Disease | 32 | 2006-07-28actual | — | 2022-01-31 |
| Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's DiseaseNCT00294112Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 PointsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells | Crohn's Disease | 10 | 2006-07-21actual | — | 2020-04-02 |
| Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsNCT00284986Response by Day 28Open-label · Treatment | Phase 2 | Completed | Drug: Prochymal | Graft Versus Host Disease | 11 | 2006-04-25actual | — | 2025-10-30 |
| Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHDNCT00759018expanded access | — | No longer available | Biological: remestemcel-L | Graft vs Host Disease, Graft-Versus-Host Disease | — | — | — | 2020-03-09 |
| Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)NCT00826046expanded access | — | No longer available | Drug: Prochymal® | Graft-Versus-Host Disease | — | — | — | 2020-03-09 |
| Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's DiseaseNCT01510431expanded access | — | No longer available | Drug: PROCHYMAL (remestemcel-L) | Crohn's Disease | — | — | — | 2020-03-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19